Hansoh Pharmaceutical Says IgG4-Related Disease Drug Gets Priority Review from China Regulator

MT Newswires Live

02/10

Hansoh Pharmaceutical Group (HKG:3692) said a new indication for the inebilizumab injection to treat immunoglobulin G4-related disease has been included in the Priority Review and Approval Procedure by the National Medical Products Administration of China.

The pharmaceutical company had entered into an agreement with Viela Bio to obtain an exclusive license to develop and commercialize the drug in China's mainland, Hong Kong, and Macao, a Monday Hong Kong bourse filing said.

Viela Bio has since been acquired by Horizon Therapeutics, which was bought by Amgen in 2023.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2510288438"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2510288438\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2510288438?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-10 15:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2510288438","market":"sg","top_or_hot":-1,"title":"Hansoh Pharmaceutical Says IgG4-Related Disease Drug Gets Priority Review from China Regulator","media":"MT Newswires Live","content":"<html><body><p> Hansoh Pharmaceutical Group (HKG:3692) said a new indication for the inebilizumab injection to treat immunoglobulin G4-related disease has been included in the Priority Review and Approval Procedure by the National Medical Products Administration of China.</p><p>The pharmaceutical company had entered into an agreement with <a href=\"https://laohu8.com/S/VIE\">Viela Bio</a> to obtain an exclusive license to develop and commercialize the drug in China's mainland, Hong Kong, and Macao, a Monday Hong Kong bourse filing said.</p><p>Viela Bio has since been acquired by Horizon <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>, which was bought by Amgen in 2023.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hansoh Pharmaceutical Says IgG4-Related Disease Drug Gets Priority Review from China Regulator</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHansoh Pharmaceutical Says IgG4-Related Disease Drug Gets Priority Review from China Regulator\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-02-10 15:25</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Hansoh Pharmaceutical Group (HKG:3692) said a new indication for the inebilizumab injection to treat immunoglobulin G4-related disease has been included in the Priority Review and Approval Procedure by the National Medical Products Administration of China.</p><p>The pharmaceutical company had entered into an agreement with <a href=\"https://laohu8.com/S/VIE\">Viela Bio</a> to obtain an exclusive license to develop and commercialize the drug in China's mainland, Hong Kong, and Macao, a Monday Hong Kong bourse filing said.</p><p>Viela Bio has since been acquired by Horizon <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>, which was bought by Amgen in 2023.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1583","symbol_name":"高瓴概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2510288438","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2510288438","pubTimestamp":1739172326,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Hansoh Pharmaceutical Group  said a new indication for the inebilizumab injection to treat immunoglobulin G4-related disease has been included in the Priority Review and Approval Procedure by the National Medical Products Administration of China.The pharmaceutical company had entered into an agreement with Viela Bio to obtain an exclusive license to develop and commercialize the drug in China's mainland, Hong Kong, and Macao, a Monday Hong Kong bourse filing said.Viela Bio has since been acquired by Horizon Therapeutics, which was bought by Amgen in 2023.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1583":"高瓴概念","BK1589":"北水核心资产","03692":"翰森制药","BK1191":"制药"},"translate_title":"豪森药业称IgG4相关疾病药物获得中国监管机构优先审查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03692":0.9},"content_text":"Hansoh Pharmaceutical Group (HKG:3692) said a new indication for the inebilizumab injection to treat immunoglobulin G4-related disease has been included in the Priority Review and Approval Procedure by the National Medical Products Administration of China.The pharmaceutical company had entered into an agreement with Viela Bio to obtain an exclusive license to develop and commercialize the drug in China's mainland, Hong Kong, and Macao, a Monday Hong Kong bourse filing said.Viela Bio has since been acquired by Horizon Therapeutics, which was bought by Amgen in 2023.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}